Colorectal Cancer Chemotherapy during COVID-19 Pandemic-Reference-Cited by-同舟云学术

Colorectal Cancer Chemotherapy during COVID-19 Pandemic

Published:2020-03 Issue:02 Volume:41 Page:156-160
ISSN:0971-5851
Container-title:Indian Journal of Medical and Paediatric Oncology
language:en
Short-container-title:Indian Journal of Medical and Paediatric Oncology

Author:

Bhethanabhotla Sainath¹,Pramanik Raja²,Srivastava Priyanka³,Mehta Prashant⁴,Patel Amol⁵,Biswas Bivas⁶,Batra Atul²,Gupta Vineet Govinda⁷,Das Chandan⁸,Mahindru Shubh⁹

Affiliation:

1. Department of Medical Oncology, Care Hospitals, Hyderabad, Telangana, India

2. Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India

3. M.S. Patel Cancer Center, Shreekrishna Hospital and Medical Research Centre, Karamsad, Gujarat, India

4. Department of Medical Oncology, Asian Institute of Medical Sciences, Faridabad, Haryana, India

5. Malignant Diseases Treatment Centre, Army Hospital Research and Referral, New Delhi, India

6. Department of Medical Oncology, Tata Medical Center, Kolkata, West Bengal, India

7. Department of Medical Oncology, Artemis Hospital, Gurgaon, Haryana, India

8. Regional Cancer Centre, Postgraduate Institute of Medical Education and Research, Chandigarh, India

9. Department of Surgical Oncology, Ivy Hospital, Mohali, Punjab, India

Abstract

AbstractThe management of patients with colorectal cancer during the current SARS-CoV2 pandemic opens a Pandora's Box. While the world is facing an unprecedented crisis of fighting a life-threatening infectious disease, patients with colorectal cancer are facing the dual challenge to fight cancer while protecting them from infection. We attempted to critically examine the existing evidence for chemotherapy in colorectal cancer in different stages of disease and suggest treatment options in these vulnerable patients. Treatment options which do not overburden existing health-care resources can be provided for patients with colorectal cancer patients requiring chemotherapy without significant compromise in efficacy or increase the risk of hospital acquired SAR-CoV-2 infection.

Publisher

Georg Thieme Verlag KG

Subject

Oncology,Pediatrics, Perinatology and Child Health

Link

http://www.thieme-connect.de/products/ejournals/pdf/10.4103/ijmpo.ijmpo_149_20.pdf

Reference21 articles.

1. Cancer patients in SARS-CoV-2 infection: A nationwide analysis in China;W Liang;Lancet Oncol,2020

2. Comorbidity and its impact on 1590 patients with Covid-19 in China: A nationwide analysis;W Guan;Eur Respir J,2020

3. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial;T André;J Clin Oncol,2009

4. AJCC 8th edition: Colorectal cancer;M R Weiser;Ann Surg Oncol,2018

5. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer;D J Sargent;J Clin Oncol,2010